Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial
Adjuvante hypertherme intraperitoneale Chemotherapie bei Patient:innen mit lokal fortgeschrittenem Kolonkarzinom (COLOPEC): 5-Jahres-Ergebnisse einer randomisierten multizentrischen Studie
Journal of Clinical Oncology · 10.01.2024 · 42 (2) · 140-145
DOI: 10.1200/jco.22.02644 ↗Auf einen Blick
In der COLOPEC-Studie zeigte adjuvante HIPEC plus systemische Chemotherapie nach 5 Jahren keinen Vorteil gegenüber alleiniger systemischer Chemotherapie. Auch die peritoneale Metastasen-freie, krankheitsfreie und Gesamtüberlebensrate unterschieden sich nicht.
Fragestellung
Verbessert adjuvante HIPEC nach kurativer Operation bei Hochrisiko-Kolonkarzinom die 5-Jahres-Onkologie im Vergleich zur alleinigen adjuvanten systemischen Chemotherapie?
Methode
Randomisierte multizentrische Studie; Patient:innen mit klinischem oder pathologischem T4N0-2M0 oder perforiertem Kolonkarzinom; 1:1-Zuteilung zu systemischer Chemotherapie plus HIPEC oder nur systemischer Chemotherapie; Intention-to-treat-Analyse; medianes Follow-up 59 Monate.
Ergebnisse
202 Patient:innen. 5-Jahres-Gesamtüberleben: 69,6 % vs. 70,9 % (P = .692). Peritoneale Metastasen-freie Überlebensrate: 63,9 % vs. 63,2 % (P = .907). Krankheitsfreies Überleben: 55,7 % vs. 52,3 % (P = .875). Keine Unterschiede in der Lebensqualität.
Schlussfolgerung der Autor:innen
Die Autor:innen folgern, dass adjuvante HIPEC weiterhin nur im Studiensetting durchgeführt werden sollte.
Kernaussagen
- Kein Unterschied im 5-Jahres-Gesamtüberleben
- Kein Vorteil bei peritonealer Metastasen-freiem Überleben
- Keine Unterschiede in den Lebensqualitäts-Outcomes
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2024. Verfasst von Emma Sophia Zwanenburg und 29 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Peritoneal Neoplasms, Hyperthermia, Induced, Colonic Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Whether adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) might prevent peritoneal metastases after curative surgery for high-risk colon cancer is an ongoing debate. This study aimed to determine 5-year oncologic outcomes of the randomized multicenter COLOPEC trial, which included patients with clinical or pathologic T4N0-2M0 or perforated colon cancer and randomly assigned (1:1) to either adjuvant systemic chemotherapy and HIPEC (n = 100) or adjuvant systemic chemotherapy alone (n = 102). HIPEC was performed using a one-time administration of oxaliplatin (460 mg/m 2 , 30 minutes, 42°C, concurrent fluorouracil/leucovorin intravenously), either simultaneously (9%) or within 5-8 weeks (91%) after primary tumor resection. Outcomes were analyzed according to the intention-to-treat principle. Long-term data were available of all 202 patients included in the COLOPEC trial, with a median follow-up of 59 months (IQR, 54.5-64.5). No significant difference was found in 5-year overall survival rate between patients assigned to adjuvant HIPEC followed by systemic chemotherapy or only adjuvant systemic chemotherapy (69.6% v 70.9%, log-rank; P = .692). Five-year peritoneal metastases-free survival rates were 63.9% and 63.2% ( P = .907) and 5-year disease-free survival was 55.7% and 52.3% (log-rank; P = .875), respectively. No differences in quality-of-life outcomes were found. Our findings implicate that adjuvant HIPEC should still be performed in trial setting only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Amsterdam UMC Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.
- UMC Utrecht, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands.
- Netherlands Cancer Institute, Department of Pathology, Amsterdam, the Netherlands.
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- Amsterdam UMC Location University of Amsterdam, Department of Radiation Oncology, Amsterdam, the Netherlands.
ORCID-Profile: Emma Sophia Zwanenburg, P Snaebjornsson, Johannes Crezee, Andre J A Bremers, Patrick H J Hemmer, M Kusters, J B Tuynman, David D E Zimmerman, Marcel G W Dijkgraaf, Pieter J Tanis
Zitieren
APA
Zwanenburg, E. S., El Klaver, C., Wisselink, D. D., Punt, C. J. A., Snaebjornsson, P., Crezee, J., Aalbers, A. G. J., Brandt-Kerkhof, A. R. M., Bremers, A. J. A., Burger, P. J. W. A., Fabry, H. F. J., Ferenschild, F. T. J., Festen, S., van Grevenstein, W. M. U., Hemmer, P. H. J., de Hingh, I. H. J. T., Kok, N. F. M., Kusters, M., Musters, G. D., …, & COLOOPEC Collaborators Group (2024). Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial. Journal of Clinical Oncology, 42(2), 140-145. https://doi.org/10.1200/jco.22.02644
Vancouver
Zwanenburg ES, El Klaver C, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, et al. Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial. Journal of Clinical Oncology. 2024;42(2):140-145. doi:10.1200/jco.22.02644
BibTeX
@article{Zwanenburg2024,
author = {Zwanenburg, Emma Sophia and El Klaver, Charlotte and Wisselink, Daniel D and Punt, Cornelis J A and Snaebjornsson, P and Crezee, Johannes and Aalbers, Arend G J and Brandt-Kerkhof, Alexandra R M and Bremers, Andre J A and Burger, Pim J W A and Fabry, Hans F J and Ferenschild, Floris T J and Festen, Sebastiaan and van Grevenstein, Wilhemina M U and Hemmer, Patrick H J and de Hingh, Ignace H J T and Kok, Niels F M and Kusters, M and Musters, G D and Schoonderwoerd, Lotte and Tuynman, J B and van de Ven, Anthony W H and van Westreenen, Henderik L and Wiezer, M J and Zimmerman, David D E and van Zweeden, Annette and Dijkgraaf, Marcel G W and Tanis, Pieter J and COLOPEC Collaborators Group, COLOPEC Collaborators Group and COLOOPEC Collaborators Group, COLOOPEC Collaborators Group},
title = {Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {2},
pages = {140--145},
doi = {10.1200/jco.22.02644}
}
EUVIMED